非小细胞肺癌egfr基因检测突变分析.docxVIP

非小细胞肺癌EGFR基因检测突变分析 摘 要 　　本课题主要研究非小细胞肺癌中EGFR 基因突变情况，选取2018年8月~2021年2月间收存的肺癌标本作为研究对象，首先使用显微切割法对肿瘤细胞群富集的肿瘤组织用无菌手术刀进行刮片收集，用商业化石蜡提取试剂盒提取 DNA，然后运用一代测序检测 EGFR 突变状态，开展 EGFR 体细胞突变检测。结果：结合EGFR 片段和 Applied Biosystems的峰图分析测序结果，一共检测出肺腺癌EGFR阳性突变共64例，突变率是 48.12 %，肺鳞癌 EGFR 阳性突变为1例，其突变率是14.28%。结论：可以得出肺腺癌患者中EGFR 的阳性突变概率较高，鳞癌的突变相对来讲是比较低的，检测基因不但可以协助早期临床诊断，而且也可以为肺癌的靶向治疗及预后评估提供有力的依据。 关键词：基因检测 非小细胞肺癌 EGFR Abstract 　　This project mainly studies the EGFR gene mutations in non-small cell lung cancer. The lung cancer specimens collected between August 2018 and February 2021 are selected as the research object. First, the microdissection method is used for tumor tissues enriched by tumor cell populations. A sterile scalpel is used for scraping collection, a commercial paraffin extraction kit is used to extract DNA, and then first-generation sequencing is used to detect EGFR mutation status and carry out EGFR somatic mutation detection. Results: Combining EGFR fragments and Applied Biosystems peak pattern analysis and sequencing results, a total of 64 cases of lung adenocarcinoma EGFR gene positive mutations were detected, the probability of mutation was 48.12%, and 1 case of lung squamous cell carcinoma EGFR gene positive mutations, and the mutation rate was 14.28%. Conclusion: It can be concluded that the positive mutation probability of EGFR in patients with lung adenocarcinoma is relatively high, and the mutation of squamous cell carcinoma is relatively low. Detection of genes can not only assist in early clinical diagnosis, but also can be targeted therapy and prognosis for lung cancer Evaluation provides a strong basis. 　　Keywords: gene detection non-small cell lung cancer EGFR 1 前 言 　　肺癌一直是个困扰世界的主要公共卫生问题，近几十年来腺癌中肺腺癌的构成比例持续不断地上涨,因患上肺癌而死亡的人数以及在全球中其发病的频率一并上升到恶性肿瘤的首位,严重威胁着人类的健康, 肺鳞状细胞癌的发病率最近几年来呈下滑的趋势，曾有研究指出, 全世界范围内肺腺癌已逐步演变成最常见的类型，发病率已远超过鳞癌或其他肺癌类型。[1] 　　随着我国市场经济的快速发展，人们日常的生活习惯的转变以及人口老龄化加重，我国肺癌患者发病与患病的比例呈现出明显的逐年上升趋势。肺癌的患病率在男性之中处在第一位,在女性癌症类型中只是落后于乳腺癌,处在第二。其中非小细胞肺癌(non-small cell lung cance